Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 25 for:    parkinson, stem

A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient (hNSCPD)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Chun-Feng Liu, Second Affiliated Hospital of Soochow University
ClinicalTrials.gov Identifier:
NCT03128450
First received: February 9, 2017
Last updated: May 21, 2017
Last verified: May 2017
  Purpose
This Pilot study will evaluate the safety and Efficacy of an investigational cell transplantation therapy, h-NSC, in patients with Parkinson's disease, through nasal drug delivery, a new delivery way. All patients will receive the therapy, which consists of human neural stem cells,

Condition Intervention Phase
Parkinson Disease
Biological: human neural stem cell
Phase 2
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Second Affiliated Hospital of Soochow University:

Primary Outcome Measures:
  • The change of Unified Parkinson's Disease Reting Scale(UPDRS)score from baseline [ Time Frame: Baseline and 16, 28 weeks ]

    Improvement rate of UPDRS motor score defined as below:

    Reduction rate =(baseline score 16, 28 weeks score after therapy)/ baseline score×100%.

    Based on reduction rate, the efficacy can be defined as complete remission, partial remission, effective and invalid The reduction rate will be 100%, >50%, >25-50%, ≤ 25% for complete remission, partial remission, effective and invalid.

    The improvement rate =[(complete+partial+effective patient number)/total patient number]×100%



Secondary Outcome Measures:
  • motor function index [ Time Frame: baseline and 16, 28 weeks ]
    Hoehn-Yahr modified score

  • Non-motor function score:cognitive function [ Time Frame: baseline and 16, 28 weeks ]
    Minimum Mental State Examination and Montreal Cognitive Assessment to assess cognitive function

  • Non-motor function score:smell [ Time Frame: baseline and 16, 28 weeks ]
    Argentina Hyposmia Rating Scales is used to detect the smell

  • Non-motor function score:fatigue [ Time Frame: baseline and 16, 28 weeks ]
    Fatigue Severity Scale to assess the extent of fatigue

  • Non-motor function score:emotion [ Time Frame: baseline and 16, 28 weeks ]
    Hamilton Depression Scale to evaluate the degree of depression, Hamilton Anxiety Scale to evaluate the degree of anxiety

  • Non-motor function score:non-motor symptoms [ Time Frame: baseline and 16, 28 weeks ]
    non-motor symptoms in PD patients is evaluated used Non-motor Symptoms Questionnaire

  • Non-motor function score:autonomic symptoms [ Time Frame: baseline and 16, 28 weeks ]
    The scale for outcomes in PD for autonomic symptoms to assess autonomic dysfunction

  • Non-motor function score:the quality of life. [ Time Frame: baseline and 16, 28 weeks ]
    The 39-item Parkinson's disease questionnaire to assess the quality of life.

  • Immunological index [ Time Frame: baseline and 16, 28 weeks ]
    CD3(%),CD4(%),CD8(%),Treg cells(%)

  • Imaging index [ Time Frame: baseline and 16, 28 weeks ]
    Magnetic Resonance Imaging or positron emission tomography

  • Blood routine examination [ Time Frame: baseline and 16, 28 weeks ]
    Blood routine examination includes the total number of red blood cells, hemoglobin, total number of white blood cells, white blood cells count, platelet count.

  • Biochemical routine examination [ Time Frame: baseline and 16, 28 weeks ]
    Biochemical routine examination includes liver function, renal function, blood glucose, blood lipid

  • Safety index [ Time Frame: 1,2,3,4,weeks and 16, 28 weeks ]
    Adverse Event and Serious Adverse Event


Other Outcome Measures:
  • PD therapy drugs [ Time Frame: baseline and 16, 28 weeks ]
    Reduction rate of PD therapy drugs


Estimated Enrollment: 12
Anticipated Study Start Date: May 21, 2017
Estimated Study Completion Date: November 1, 2018
Estimated Primary Completion Date: June 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: h-NSC arm

human neural stem cell: 100ul/vessel,2 vessel/one bag,≥2×10 6cells/vessel,produced by Shanghai Angecon Biotechology Cooperate.

One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time.

Biological: human neural stem cell
human neural stem cell: 100ul/vessel,2 vessel/one bag,≥2×10 6cells/vessel

Detailed Description:

h-NSC is a cellular therapeutic consisting of human fetal neural stem cells (h-NSC). h-NSC injection will be delivered through nasal way for patients with Parkinson's disease (PD).

The study will enroll 12 moderate to severe PD patients to be treated with the cell injection therapy at the same dose. The total therapy course will be four weeks,one dose for one week. The follow up will be two times within 24 weeks after finishing the treatment. The main objective of the study is to evaluate the efficacy and safety of the cell transplantation by this new delivery way.

  Eligibility

Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient diagnosed with idiopathic PD, at least with two key symptoms (Static tremor, bradykinesia, rigidity ) , without any other evidence of Secondary Parkinson's syndrome.
  • Disease course ≥7 years,modified Hoehn-Yahr is 3-5 stage
  • Patient age ≥35 years
  • Patients receiving a stable dose of levodopa for at least 1 months with the expectation that the treatment will remain unchanged throughout the course of the study
  • The doses of levodopa ≥300mg •Signed informed consent form (ICF) by patient self or his law-in relationship before enrollment.

Exclusion Criteria:

  • Hepatic dysfunction(transaminase ≥1.5 normal range), Renal dysfunction(Cr>2.0mg/dl or 177μmol/L),Cardiac dysfunction or other severe systematic diseases etc.
  • Suffering malignancy or during anti-cancer treatment period.
  • Pregancy, lactation or possible pregancy and plan to pregancy patient
  • Attended other intervention clinical trial within 3 months aftre getting ICF, or during other ongoing intervention clinical trial
  • Investigator think inappropriate patient for this protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03128450

Locations
China, Jiangsu
Department of Neurology, Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215004
Sponsors and Collaborators
Second Affiliated Hospital of Soochow University
Investigators
Principal Investigator: Jie Li Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou
  More Information

Publications:
Responsible Party: Chun-Feng Liu, Professor, Second Affiliated Hospital of Soochow University
ClinicalTrials.gov Identifier: NCT03128450     History of Changes
Other Study ID Numbers: Second Affiliated Hospital
Study First Received: February 9, 2017
Last Updated: May 21, 2017
Individual Participant Data  
Plan to Share IPD: Undecided
Plan Description: Will decisde if the IPD based on patient consent

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Second Affiliated Hospital of Soochow University:
Parkinson Disease
Neural stem cell
Nasal delivery

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 23, 2017